This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Larson, J. S. Articles by Lai, M. T. Search for Related Content PubMed PubMed Citation Articles by Larson, J. S. Articles by Lai, M. T.

A BRCA1 Mutant Alters G₂-M Cell Cycle Control in Human Mammary Epithelial Cells¹

Cancer Research Division, Lilly Research Labs, Lilly Corporate Center, Indianapolis, Indiana 46285

Mutations in BRCA1 increase the risk of breast and ovarian cancer. Although the mechanism by which mutant BRCA1 alters growth regulation is unknown, the COOH terminus of BRCA1 appears to play a critical role. To examine this, we introduced a vector expressing BRCA1 COOH-terminal residues 1293–1863 (CT-BRCA1) into nontumorigenic human breast epithelial cells. Overexpression of CT-BRCA1 led to a reduction in the doubling time (from 64 to 44 h) and a decreased reliance on growth factors, suggesting that this CT-BRCA1 may function in a dominant-negative manner. Expression of CT-BRCA1 induced alterations in cell cycle control, mainly in G₂-M, including a loss of G₂-M block by colchicine. These results suggest that one function of BRCA1-related growth control occurs by governing checkpoint(s) between DNA replication and mitosis.

¹ This work was supported by Eli Lilly and Co.

² To whom requests for reprints should be addressed at Drop Code 0434, Cancer Research Division, Lilly Research Labs, Lilly Corporate Center, Indianapolis, IN 46285. Phone: (317) 276-6932; Fax: (317) 276-1414; E-mail: Lai_Mei_Huei@Lilly.com.

Received 5/30/97. Accepted 7/ 1/97.

This article has been cited by other articles:

				S.-K. Sha, T. Sato, H. Kobayashi, M. Ishigaki, S. Yamamoto, H. Sato, A. Takada, S. Nakajyo, Y. Mochizuki, J. M. Friedman, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint Mol. Cancer Ther., January 1, 2007; 6(1): 147 - 153. [Abstract] [Full Text] [PDF]

				T.J. Bowen, H. Yakushiji, C. Montagna, S. Jain, T. Ried, and A. Wynshaw-Boris Atm Heterozygosity Cooperates with Loss of Brca1 to Increase the Severity of Mammary Gland Cancer and Reduce Ductal Branching Cancer Res., October 1, 2005; 65(19): 8736 - 8746. [Abstract] [Full Text] [PDF]

				E. D. Coene, M. S. Hollinshead, A. A.T. Waeytens, V. R.J. Schelfhout, W. P. Eechaute, M. K. Shaw, P. M.V. Van Oostveldt, and D. J. Vaux Phosphorylated BRCA1 Is Predominantly Located in the Nucleus and Mitochondria Mol. Biol. Cell, February 1, 2005; 16(2): 997 - 1010. [Abstract] [Full Text] [PDF]

				J. P. McPherson, B. Lemmers, A. Hirao, A. Hakem, J. Abraham, E. Migon, E. Matysiak-Zablocki, L. Tamblyn, O. Sanchez-Sweatman, R. Khokha, et al. Collaboration of Brca1 and Chk2 in tumorigenesis Genes & Dev., May 15, 2004; 18(10): 1144 - 1153. [Abstract] [Full Text] [PDF]

				T I Orban and E Olah Emerging roles of BRCA1 alternative splicing Mol. Pathol., August 1, 2003; 56(4): 191 - 197. [Abstract] [Full Text] [PDF]

				W. Fan, S. Jin, T. Tong, H. Zhao, F. Fan, M. J. Antinore, B. Rajasekaran, M. Wu, and Q. Zhan BRCA1 Regulates GADD45 through Its Interactions with the OCT-1 and CAAT Motifs J. Biol. Chem., March 1, 2002; 277(10): 8061 - 8067. [Abstract] [Full Text] [PDF]

				H. Wang, Z.-C. Zeng, T.-A. Bui, S. J. DiBiase, W. Qin, F. Xia, S. N. Powell, and G. Iliakis Nonhomologous End-Joining of Ionizing Radiation-induced DNA Double-Stranded Breaks in Human Tumor Cells Deficient in BRCA1 or BRCA2 Cancer Res., January 1, 2001; 61(1): 270 - 277. [Abstract] [Full Text]

				K. K. Khanna Cancer Risk and the ATM Gene: a Continuing Debate J Natl Cancer Inst, May 17, 2000; 92(10): 795 - 802. [Abstract] [Full Text] [PDF]

				M. Motwani, X.-k. Li, and G. K. Schwartz Flavopiridol, a Cyclin-dependent Kinase Inhibitor, Prevents Spindle Inhibitor-induced Endoreduplication in Human Cancer Cells Clin. Cancer Res., March 1, 2000; 6(3): 924 - 932. [Abstract] [Full Text]

				N. L. S. Tang, C.-P. Pang, W. Yeo, K.-W. Choy, P. K. Lam, M. Suen, L. K. Law, W. W. K. King, P. Johnson, and M. Hjelm Prevalence of Mutations in the BRCA1 Gene Among Chinese Patients With Breast Cancer J Natl Cancer Inst, May 19, 1999; 91(10): 882 - 885. [Full Text] [PDF]

				L.-C. Hsu and R. L. White BRCA1 is associated with the centrosome during mitosis PNAS, October 27, 1998; 95(22): 12983 - 12988. [Abstract] [Full Text] [PDF]

				X. Yu, L. C. Wu, A. M. Bowcock, A. Aronheim, and R. Baer The C-terminal (BRCT) Domains of BRCA1 Interact in Vivo with CtIP, a Protein Implicated in the CtBP Pathway of Transcriptional Repression J. Biol. Chem., September 25, 1998; 273(39): 25388 - 25392. [Abstract] [Full Text] [PDF]

				A. Bhattacharyya, U. S. Ear, B. H. Koller, R. R. Weichselbaum, and D. K. Bishop The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin J. Biol. Chem., July 28, 2000; 275(31): 23899 - 23903. [Abstract] [Full Text] [PDF]

				Y.-F. Hu, T. Miyake, Q. Ye, and R. Li Characterization of a Novel Trans-Activation Domain of BRCA1 That Functions in Concert with the BRCA1 C-terminal (BRCT) Domain J. Biol. Chem., December 22, 2000; 275(52): 40910 - 40915. [Abstract] [Full Text] [PDF]

				X. Yu and R. Baer Nuclear Localization and Cell Cycle-specific Expression of CtIP, a Protein That Associates with the BRCA1 Tumor Suppressor J. Biol. Chem., June 9, 2000; 275(24): 18541 - 18549. [Abstract] [Full Text] [PDF]